Ivosidenib in Chinese patients (pts) with relapsed/refractory acute myeloid leukemia (R/R AML) with an IDH1 mutation: Results from a bridging registrational study

被引：0

作者：

Wang, J. ^{[1
,2
]}

Jin, J. ^{[3
]}

Yin, Q. ^{[4
]}

Sun, M. ^{[1
,2
]}

Liang, Y. ^{[5
]}

Chang, C. ^{[6
]}

Zheng, J. ^{[7
]}

Li, J. ^{[8
,11
]}

Ji, C. ^{[9
]}

Zhang, J. ^{[10
]}

Li, J. ^{[8
,11
]}

Gong, Y. ^{[12
]}

Luo, S. ^{[13
]}

Zhang, Y. ^{[14
]}

Chen, R. ^{[14
]}

Shen, Z. ^{[14
]}

Yu, X. ^{[15
]}

Liu, K. ^{[14
]}

Yang, J. ^{[14
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, Natl Clin Res Ctr Blood Dis, Tianjin, Peoples R China

[2] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Tianjin, Peoples R China

[3] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Hematol, Hangzhou, Peoples R China

[4] Henan Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China

[5] Sun Yat Sen Univ, Ctr Canc, Dept Hematol & Oncol, Guangzhou, Peoples R China

[6] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Hematol, Shanghai, Peoples R China

[7] Fujian Med Univ, Union Hosp, Dept Hematol, Fuzhou, Peoples R China

[8] Peking Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China

[9] Shandong Univ, Qilu Hosp, Dept Hematol, Jinan, Peoples R China

[10] Soochow Univ, Affiliated Hosp 1, Dept Hematol, Suzhou, Peoples R China

[11] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Hematol, Shanghai, Peoples R China

[12] Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Peoples R China

[13] Wenzhou Med Univ, Affiliated Hosp 1, Dept Hematol, Wenzhou, Peoples R China

[14] CStone Pharmaceut Suzhou Co Ltd, Clin Dev, Suzhou, Peoples R China

[15] CStone Pharmaceut Suzhou Co Ltd, Translat Med, Suzhou, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.118

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

825O

引用

页码：S773 / S773

页数：1

共 50 条

[1] Ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation
Pasquier, Florence
Chahine, Claude
Marzac, Christophe
de Botton, Stephane
EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2020, 5 (06): : 429 - 438
[2] Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study.
Pollyea, Daniel Aaron
Dinardo, Courtney Denton
de Botton, Stephane
Stein, Eytan
Roboz, Gail J.
Mims, Alice S.
Swords, Ronan T.
Altman, Jessica K.
Collins, Robert
Mannis, Gabriel N.
Uy, Geoffrey L.
Donnellan, William Bruce
Pigneux, Arnaud
Fathi, Amir Tahmasb
Liu, Hua
Wu, Bin
Attar, Eyal C.
Tallman, Martin S.
Stone, Richard M.
Kantarjian, Hagop M.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[3] Ivosidenib (IVO) prior to hematopoietic cell transplant for patients with IDH1-mutant relapsed or refractory acute myeloid leukemia (R/R AML).
Dinardo, Courtney Denton
Stein, Eytan
Pigneux, Arnaud
Altman, Jessica K.
Collins, Robert
Erba, Harry Paul
Watts, Justin M.
Uy, Geoffrey L.
Kapsalis, Stephanie M.
Liu, Hua
Winkler, Thomas
Roboz, Gail J.
de Botton, Stephane
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[4] Ivosidenib-azacitidine in acute myeloid leukemia with IDH1 R132 mutation
Mechelfekh, Yaquine
Gastaud, Lauris
BULLETIN DU CANCER, 2023, 110 (12) : 1232 - 1233
[5] Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study
DiNardo, Courtney D.
Stein, Eytan M.
de Botton, Stephane
Roboz, Gail J.
Altman, Jessica K.
Mims, Alice S.
Swords, Ronan
Collins, Robert H.
Mannis, Gabriel N.
Pollyea, Daniel A.
Donnellan, Will
Fathi, Amir T.
Pigneux, Arnaud
Erba, Harry P.
Prince, Gabrielle T.
Stein, Anthony S.
Uy, Geoffrey L.
Foran, James M.
Traer, Elie
Stuart, Robert K.
Arellano, Martha L.
Slack, James L.
Sekeres, Mikkael A.
Willekens, Christophe
Choe, Sung
Wang, Hongfang
Zhang, Vickie
Yen, Katharine E.
Kapsalis, Stephanie M.
Yang, Hua
Dai, David
Fan, Bin
Goldwasser, Meredith
Liu, Hua
Agresta, Sam
Wu, Bin
Attar, Eyal C.
Tallman, Martin S.
Stone, Richard M.
Kantarjian, Hagop M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S204 - S205
[6] Venetoclax in Combination With Low-Dose Cytarabine and/or Actinomycin D in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Patients With IDH1 or IDH2 Mutations
Daukelaite, Guoda
Vasilevska, Dominika
Vaitekenaite, Vilmante
Trociukas, Igoris
Pileckyte, Regina
Griskevicius, Laimonas
Zucenka, Andrius
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S293 - S294
[7] Clinical pharmacokinetics and pharmacodynamics of ivosidenib in Chinese patients with relapsed or refractory IDH1-mutated acute myeloid leukemia
Yue, Zenglian
Pan, Chaohsuan
Wang, Siyuan
Tse, Archie N.
Sheng, Yucheng
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (01) : 105 - 113
[8] Clinical pharmacokinetics and pharmacodynamics of ivosidenib in Chinese patients with relapsed or refractory IDH1-mutated acute myeloid leukemia
Zenglian Yue
Chaohsuan Pan
Siyuan Wang
Archie N. Tse
Yucheng Sheng
European Journal of Clinical Pharmacology, 2024, 80 : 105 - 113
[9] A Phase 1 Study of WU-NK-101 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
Cashen, Amanda F.
Liu, Hongtao
Al Malki, Monzr M.
Zeidner, Joshua F.
Foster, Matthew C.
Pannunzio, Angela
Ramsey, Brett
Baughman, Jan
Muth, John
Bakkacha, Ouiam
McNulty, Eileen
Jacobs, Kenneth
Davidson-Moncada, Jan K.
Wei, Andrew H.
BLOOD, 2022, 140 : 12740 - 12741
[10] A Phase 1 Trial of Valemetostat in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
Erba, Harry P.
Oluwole, Olalekan O.
Bixby, Dale
Rampal, Raajit K.
Fathi, Amir T.
Paliwal, Prashni
Jin, Jin
Inoue, Ai
Daver, Naval
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S311 - S312

← 1 2 3 4 5 →